Hyphens Pharma International Ltd
SGX:1J5
Income Statement
Earnings Waterfall
Hyphens Pharma International Ltd
Revenue
|
195.4m
SGD
|
Cost of Revenue
|
-125.9m
SGD
|
Gross Profit
|
69.5m
SGD
|
Operating Expenses
|
-54.3m
SGD
|
Operating Income
|
15.2m
SGD
|
Other Expenses
|
-5m
SGD
|
Net Income
|
10.2m
SGD
|
Income Statement
Hyphens Pharma International Ltd
Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Jun-2021 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | Jun-2024 | Dec-2024 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||||||||||||
Revenue |
113
N/A
|
117
+3%
|
117
+0%
|
117
+1%
|
121
+3%
|
117
-3%
|
115
-2%
|
117
+1%
|
119
+2%
|
124
+4%
|
125
+1%
|
126
+1%
|
121
-4%
|
126
+4%
|
126
+0%
|
141
+12%
|
162
+15%
|
156
-4%
|
171
+9%
|
196
+15%
|
195
0%
|
|
Gross Profit | ||||||||||||||||||||||
Cost of Revenue |
(76)
|
(79)
|
(78)
|
(78)
|
(80)
|
(77)
|
(76)
|
(76)
|
(77)
|
(80)
|
(81)
|
(82)
|
(77)
|
(78)
|
(78)
|
(87)
|
(100)
|
(97)
|
(109)
|
(127)
|
(126)
|
|
Gross Profit |
37
N/A
|
38
+1%
|
39
+3%
|
40
+2%
|
41
+3%
|
41
0%
|
40
-2%
|
41
+3%
|
43
+4%
|
44
+3%
|
44
+0%
|
44
-1%
|
44
+0%
|
47
+9%
|
48
+1%
|
54
+13%
|
63
+15%
|
60
-5%
|
62
+4%
|
69
+11%
|
70
+1%
|
|
Operating Income | ||||||||||||||||||||||
Operating Expenses |
(29)
|
(30)
|
(31)
|
(32)
|
(32)
|
(34)
|
(33)
|
(34)
|
(34)
|
(35)
|
(34)
|
(34)
|
(37)
|
(38)
|
(40)
|
(43)
|
(48)
|
(48)
|
(50)
|
(52)
|
(54)
|
|
Selling, General & Administrative |
(29)
|
(29)
|
(30)
|
(32)
|
(32)
|
(33)
|
(33)
|
(34)
|
(35)
|
(35)
|
(36)
|
(36)
|
(36)
|
(39)
|
(39)
|
(44)
|
(47)
|
(48)
|
(50)
|
(52)
|
(55)
|
|
Research & Development |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
(1)
|
0
|
(1)
|
0
|
(0)
|
0
|
0
|
|
Other Operating Expenses |
0
|
(0)
|
(1)
|
(1)
|
0
|
(2)
|
(1)
|
(1)
|
1
|
1
|
2
|
2
|
0
|
1
|
0
|
1
|
0
|
1
|
0
|
1
|
1
|
|
Operating Income |
8
N/A
|
8
-9%
|
8
+5%
|
7
-7%
|
9
+19%
|
7
-26%
|
6
-2%
|
7
+15%
|
9
+16%
|
10
+11%
|
10
+7%
|
10
-6%
|
7
-27%
|
10
+36%
|
8
-16%
|
12
+46%
|
15
+28%
|
12
-20%
|
12
+2%
|
17
+38%
|
15
-10%
|
|
Pre-Tax Income | ||||||||||||||||||||||
Interest Income Expense |
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
(0)
|
0
|
0
|
(1)
|
0
|
(1)
|
(0)
|
(1)
|
|
Non-Reccuring Items |
0
|
(0)
|
(1)
|
(1)
|
(1)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
(0)
|
0
|
0
|
|
Gain/Loss on Disposition of Assets |
(0)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
(0)
|
0
|
0
|
0
|
0
|
|
Total Other Income |
(1)
|
(0)
|
(0)
|
(0)
|
(1)
|
0
|
0
|
(0)
|
(0)
|
(1)
|
(1)
|
(1)
|
(0)
|
(2)
|
(1)
|
(1)
|
(1)
|
(2)
|
(1)
|
(3)
|
(2)
|
|
Pre-Tax Income |
7
N/A
|
7
+4%
|
7
-7%
|
6
-8%
|
7
+9%
|
6
-8%
|
6
-2%
|
7
+12%
|
8
+12%
|
9
+11%
|
9
+6%
|
8
-12%
|
7
-14%
|
7
+1%
|
8
+15%
|
11
+31%
|
14
+32%
|
11
-25%
|
11
-1%
|
14
+31%
|
13
-6%
|
|
Net Income | ||||||||||||||||||||||
Tax Provision |
(1)
|
(1)
|
(1)
|
(1)
|
(2)
|
(1)
|
(1)
|
(1)
|
(1)
|
(2)
|
(2)
|
(1)
|
(1)
|
(1)
|
(1)
|
(2)
|
(3)
|
(2)
|
(2)
|
(3)
|
(2)
|
|
Income from Continuing Operations |
6
|
6
|
6
|
5
|
5
|
5
|
5
|
6
|
7
|
7
|
8
|
7
|
6
|
6
|
7
|
9
|
11
|
9
|
9
|
11
|
11
|
|
Income to Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
0
|
(0)
|
(1)
|
(1)
|
|
Net Income (Common) |
6
N/A
|
6
+3%
|
6
-9%
|
5
-9%
|
5
+4%
|
5
-7%
|
5
+0%
|
6
+12%
|
7
+15%
|
7
+11%
|
8
+7%
|
7
-12%
|
6
-9%
|
6
+1%
|
7
+10%
|
9
+27%
|
11
+31%
|
9
-23%
|
9
-2%
|
10
+22%
|
10
-2%
|
|
EPS (Diluted) |
0.03
N/A
|
0.03
N/A
|
0.03
N/A
|
0.02
-33%
|
0.02
N/A
|
0.02
N/A
|
0.02
N/A
|
0.02
N/A
|
0.02
N/A
|
0.02
N/A
|
0.03
+50%
|
0.02
-33%
|
0.02
N/A
|
0.02
N/A
|
0.02
N/A
|
0.03
+50%
|
0.04
+33%
|
0.03
-25%
|
0.03
N/A
|
0.03
N/A
|
0.03
N/A
|